Free Trial
NASDAQ:ELDN

Eledon Pharmaceuticals Q1 2025 Earnings Report

Eledon Pharmaceuticals logo
$3.80 0.00 (0.00%)
Closing price 05/15/2026 04:00 PM Eastern
Extended Trading
$3.72 -0.08 (-2.08%)
As of 07:18 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Eledon Pharmaceuticals EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.28
Beat/Miss
Beat by +$0.20
One Year Ago EPS
N/A

Eledon Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Eledon Pharmaceuticals Announcement Details

Quarter
Q1 2025
Time
Before Market Opens
Conference Call Date
Wednesday, May 14, 2025
Conference Call Time
12:00AM ET

Eledon Pharmaceuticals Earnings Headlines

Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Eledon Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email.

About Eledon Pharmaceuticals

Eledon Pharmaceuticals (NASDAQ:ELDN) (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of therapies for diseases characterized by smooth muscle dysfunction. The company leverages a proprietary ion-channel modulation platform to identify and optimize small-molecule compounds that can either restore or inhibit smooth muscle activity, with the goal of addressing gastrointestinal, hepatic and cardiovascular disorders.

Eledon’s pipeline comprises several preclinical and early-phase clinical programs targeting high-unmet-need indications. Its lead candidate has advanced into initial human trials, and additional assets are in IND-enabling studies. To support development, the company collaborates with academic research institutions and specialty contract development organizations, drawing on external expertise for pharmacology, toxicology and clinical trial execution.

Based in the United States with operations in Europe, Eledon Pharmaceuticals conducts multi-center studies across North America and the EMEA region. The company’s leadership team brings together experienced drug development professionals, clinical operations specialists and regulatory experts, positioning Eledon to advance its portfolio toward late-stage trials and eventual commercialization.

View Eledon Pharmaceuticals Profile